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Abstract
Background: Colchicine is used in the treatment and prophylaxis of gout. It possesses a narrow
therapeutic window, frequently resulting in dose-limiting gastrointestinal side-effects such as
diarrhoea and emesis. As colchicine is a cellular anti-mitotic agent, the most serious effects include
myelosuppression, myoneuropathy and multiple organ failure. This occurs with intentional
overdose or with therapeutic dosing in patients with reduced clearance of colchicine due to pre-
existing renal or hepatic impairment. Acute pancreatitis has rarely been reported, and only in
association with severe colchicine overdose accompanied by multi-organ failure.
Case presentation: We report a case of acute pancreatitis without other organ toxicity related
to recent commencement of colchicine for acute gout, occurring in an elderly male with pre-
existing renal impairment.
Conclusion: 1) Colchicine should be used with care in elderly patients or patients with impaired
renal function.
2) Aside from myelosuppression, myoneuropathy and multiple organ failure, colchicine may now 
be associated with acute pancreatitis even with therapeutic dosing; this has not previously being 
reported.
Background
Colchicine is frequently used to treat and prevent recur-
rence of acute gout [1] but has a narrow therapeutic win-
dow, with dose-limiting gastrointestinal side-effects such
as diarrhoea and vomiting [2]. Colchicine toxicity relates
to its cellular anti-mitotic action and preferentially affects
tissues that have a rapid turnover [3], leading to early gas-
trointestinal failure, myelosuppression and ultimately
multi-organ failure [1,2]. Colchicine in intentional over-
dose is difficult to treat and frequently lethal [4]. Acute
pancreatitis related to colchicine has rarely been reported,
and only in the context of severe toxicity [5-7].
Case presentation
A 79 year old man presented to the Emergency Depart-
ment with severe epigastric pain, nausea, vomiting with-
out hematemesis, diarrhoea and anorexia. He has a
history of red cell and platelet transfusion dependent
myelofibrosis, iron overload due to multiple red cell
transfusion, chronic renal failure, ischemic heart disease,
left ventricular systolic dysfunction, cerebrovascular dis-
ease, peripheral vascular disease, hypertension, and
hyperlipidemia. His regular medications include
diltiazem, valacyclovir, nicorandil, bisoprolol, defero-
sirox, frusemide and glyceryl trinitrate patches. Aside from
the recent addition of colchicine, his medications are
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unchanged. The patient denied using herbal or over the
counter products. He was independent with activities of
daily living, was a life-long non-alcohol drinker and
stopped smoking decades ago. There was no history of
abdominal trauma.
The patient was alert and orientated with blood pressure
100/48 mm Hg, pulse 66/min regular, respiratory rate 20/
min, SaO2 is 97% on room air and temperature 36.8°C.
There was marked epigastric tenderness without abdomi-
nal distension. Normal bowel sounds are present. No free
subdiaphragmatic gas was visible on erect chest X-ray.
Several blood investigations were performed; serum
lipase is elevated at 859 (reference range, RR 25–300 U/L).
Serum urate is 0.92 (RR 0.15–0.5 mmol/L), albumin-cor-
rected calcium 2.38 (RR 2.15–2.6 mmol/L), sodium 136
(RR 135–145 mmol/L) and potassium 5.0 (RR 3.2–4.5
mmol/L). There was a mild deterioration of serum creati-
nine to 332 (RR 70–120 umol/L) and urea 38.9 (RR 3.0–
8.0 mmol/L). Venous blood gases showed pH of 7.24 (RR
7.35–7.45), bicarbonate 18 (RR 22–27 mmol/L), base
deficit -8.9 (RR -3.0 to +3.0 mmol/L) and lactate 1.0 (RR
0.2–2.0 mmol/L). Serum triglyceride level was 2.0 (RR
0.5–2.0 mmol/L). Liver function tests were deranged:
aspartate transaminase 206 (RR 10–45 U/L), alanine
transaminase 269 (RR 5–45 U/L), gamma glutamyl
transaminase 145 (RR 10–70 U/L), alkaline phosphatase
209 (RR 40–110 U/L) and total bilirubin 9 (RR <20
micromoles/L). Prothrombin time was 16.1 (RR 11–16
seconds), INR 1.3 and APTT 33.4 (RR 22–35 seconds).
Haematology parameters were unchanged from previous
results, with haemoglobin 118 (RR 130–180 g/L), haema-
tocrit 0.352 (RR 0.40–0.54), white cell count 7.8 (RR 4.5–
11.0 × 109/L) and platelets 34 (RR 150–400 × 109/L).
The patient recovered over 48 hours with clear oral fluids
and supportive medical treatment including intravenous
fluids and analgesia as required. This coincided with
declining lipase levels. Myelosuppression ascribable to
colchicine did not occur.
An abdominal ultrasound demonstrated normal liver tex-
ture, oedematous pancreas, and multiple small incidental
calculi within a normal walled gallbladder, no hepatobil-
iary ductal dilatation or pericholecystic fluid, normal pan-
creatic duct, enlarged spleen and multiple bilateral renal
cysts without hydronephrosis.
Discussion and conclusion
The incidence of acute pancreatitis varies in different
countries and depends on cause, with the estimated inci-
dence in England being 5.4/100 000 per year; in the
United States it is 79.8/100 000 per year [14]. Precipitants
of acute pancreatitis are extensive and wide ranging [10];
the most frequent causes are gallstones (30–60%) and
alcohol (15–30%) [8,14]. In 20% of cases, the cause
remains unidentified [8]. Drugs are implicated in only 2–
5% of cases, either by a hypersensitivity reaction or the
generation of a toxic metabolite [14], although it is fre-
quently difficult to prove causality [9].
Identifying the underlying cause of acute pancreatitis
allows avoidance or treatment of the precipitant and
improves chances of recovery [10]. This patient sustained
mild and self-limited acute pancreatitis associated with
recent commencement of colchicine for gout, which has
not previously been reported. However, comorbidities
implicated in acute pancreatitis make a trigger or co-factor
role for colchicine more likely [9], rather than colchicine
being the sole aetiological agent. In this case, microlithia-
sis [8], chronic renal failure [10,11,14] and frusemide [10]
may have set the scene for acute pancreatitis precipitated
by colchicine. With a normal bilirubin level, however, the
patient had liver function tests which were more consist-
ent with a hepatitic rather than an obstructive enzymosis.
Furthermore, he did not have hypercalcaemia or hyper-
triglyceridaemia, metabolic factors well known to contrib-
ute to pancreatic inflammation [8,14].
There was no evidence of acute seroconversion to hepati-
tis A, B, C viruses; Epstein-Barr virus, Cytomegalovirus
and herpes simplex 1 and 2 viruses. As such, acute viral
hepatitis or pancreatitis was unlikely. Non-drug aetiolo-
gies for pancreatitis in this patient (renal failure, micro-
lithiasis, ongoing use of frusemide) remained; despite
this, rapid clinical recovery occurred with withdrawal of
colchicine. This renders colchicine the most eminent asso-
ciation to pancreatitis in this case.
Sole attribution for acute pancreatitis to a single drug
remains difficult due to high rates of concurrent contribu-
tory diseases in acute pancreatitis [9]. Aside from fruse-
mide, of which there had been no recent dose escalation,
none of this patient's other prescribed medications have
been reported to increase risk of acute pancreatitis
[10,14]. Nitrates have been known to reduce pancreatitis
pain and relapse [13], with diltiazem improving survival
in rat models of acute pancreatitis [12]
There have been several reports of acute pancreatitis
related to colchicine; including accidental ingestion of a
plant (Colchicum autumnale) thought to be wild garlic [3],
intraurethral administration of colchicine for condyloma
acuminata [5], and after intentional oral overdoses of col-
chicine [6,7]. These patients had severe colchicine toxicity
associated with multi-organ failure and death in one case
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Patients with renal impairment have reduced colchicine
clearance, may be more susceptible to colchicine toxicity
and require cautious dosing [1,2]. In this case report,
acute pancreatitis occurred in an elderly man with pre-
existing renal impairment after two days of oral colchicine
1 mg daily for gout in the big toe. Unlike with colchicine
overdose-related pancreatitis [5-7], this patient did not
experience severe colchicine toxicity, myelosuppression or
deteriorating multi-organ dysfunction. Clinicians need to
be cautious when prescribing colchicine in patients with
renal impairment [1,2] as isolated acute pancreatitis (or
potentially even more severe toxicity) may occur in these
patients even with therapeutic doses of colchicine.
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